{"prompt": "['Trelagliptin-4002', 'Page 6 of 66', 'Version 2.0', 'July 5, 2017', '7.5', 'Criteria for discontinuation or withdrawal of a study subject', '28', '7.6', 'Procedures for discontinuation of individual study subjects', '29', '8.0', 'STUDY TREATMENT', '31', '8.1', 'Study drug and Comparative drug', '31', '8.1.1', 'Study drug', '31', '8.1.2', 'Comparative drug', '31', '8.2', 'Overdose of the study drug', '32', '8.3', 'Medication other than the study drug and the comparative drug', '32', '8.4', 'Allocation of the study drug and administration procedure', '33', '8.5', 'Preparation and storage of allocation list', '33', '9.0', 'CLINICAL STUDY PROTOCOL', '34', '9.1', 'Clinical study procedures', '34', '9.1.1', 'Informed consent', '34', '9.1.2', 'Demographic data and medical history', '34', '9.1.3', 'Physical examination', '34', '9.1.4', 'Body weight, height, and BMI', '34', '9.1.5', 'Concomitant drugs', '34', '9.1.6', 'Comorbidities', '35', '9.1.7', 'Laboratory tests', '35', '9.1.8 The Basic Information on Study Subject (Your Basic Profile)', '36', '9.1.9', 'DTR-QOL Questionnaire', '36', '9.1.10', 'DTSQ', '37', '9.1.11', 'Treatment Compliance', '38', '9.1.12 Hospitalization for type 2 diabetes', '38', '9.1.13 Contraception', '38', '9.1.14 Pregnancy', '38', '9.1.15 Record of study subjects who are withdrawn before randomization', '39', '9.1.16 Record of randomization', '39', '9.2', 'Implementation time point of the tests and observation', '39', '9.2.1', 'Screening period (Week -4)', '39', '9.2.2', 'Treatment period (Week 0)', '40', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 7 of 66', 'Version 2.0', 'July 5, 2017', '9.2.3', 'Treatment period (Week 4)', '40', '9.2.4 Treatment period (Week 12) or discontinuation', '41', '10.0', 'ADVERSE EVENTS', '42', '10.1', 'Definitions', '42', '10.1.1 Adverse events', '42', '10.1.2 Considerations for adverse events', '42', '10.1.3 Serious adverse event', '44', '10.1.4 Adverse events of special interest (specific adverse events)', '45', '10.1.5 Severity of adverse events', '45', '10.1.6 Causality of adverse events', '45', '10.1.7 Relationship to study procedures', '46', '10.1.8 Date of onset', '46', '10.1.9 Date of resolution', '46', '10.1.10Actions taken for the study drug or comparative drug', '47', '10.1.11Outcome', '47', '10.2 Procedures', '48', '10.2.1 Collection and reporting of adverse events and its coverage', '48', '10.2.2 Collection and reporting of serious adverse events', '49', '10.2.3 Reporting of additional information concerning adverse events', '50', '10.3', 'Follow-up of serious adverse events', '50', '10.3.1 Reporting of serious adverse events to Ethical Review Board, etc.,', 'and regulatory authorities', '50', '11.0 COMMITTEES ESTABLISHED FOR THIS STUDY', '52', '11.1', 'Clinical Study Steering Committee', '52', '12.0', 'DATA MANAGEMENT AND STORAGE OF RECORDS', '53', '12.1', 'Case report form', '53', '12.2', 'Timing of data entry into the EDC system', '54', '12.3', 'Storage of records', '54', '13.0', 'STATISTICAL ANALYSIS METHODS', '55', '13.1', 'Statistical and analytical plans', '55', '13.1.1 Analysis set', '55', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}